{"schema_version":"1.0","type":"article","title":"Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T","url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.md","lang":"zh-Hant","date":"2026-05-17","publish_at":"2026-05-17T10:30:00+08:00","updated_at":"2026-05-17","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","CAR-T","Kelonia","BD","ADC","J&J","FDA"],"summary":"【嬌生 CAR-T 戰略折戟：不是數據不夠漂亮，而是自體 CD19/CD20 CAR-T 的商業死循環開始反噬】📌 誰能想到，幾個月前還被 Johnson & Johnson 管理層高度看好的淋巴瘤","key_points":[],"facts":[],"sections":["01｜從「best-in-disease」到被終止：自體 CAR-T 的殘酷落差","02｜這不是臨床失敗，而是商業模型失敗","03｜雙靶點不是免死金牌","04｜嬌生不是放棄 CAR-T，而是把籌碼集中到更有勝率的地方","05｜LBCL 自體 CAR-T 正在從「拼數據」變成「拼生存」","06｜最該被重估的，是自體 CD19 CAR-T 的BD 大藥廠預期","07｜下一代 CAR-T 的錢，正在流向哪裡？"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Johnson & Johnson statement on investigational programs in large B-cell lymphoma","source":"","date":"","url":""},{"title":"https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma","source":"","date":"","url":"https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-investigational-programs-in-large-b-cell-lymphoma"},{"title":"www.jnj.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma","source":"","date":"","url":""},{"title":"Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dos","source":"","date":"","url":""},{"title":"www.jnj.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Page Not Found","source":"FDA","date":"","url":""},{"title":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma","source":"","date":"","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma"},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Study Details - Gilead Clinical Trials","source":"","date":"","url":""},{"title":"Study Details - Gilead Clinical Trials","source":"","date":"","url":""},{"title":"www.gileadclinicaltrials.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Johnson & Johnson reports Q1 2026 results, raises 2026 outlook","source":"Johnson & Johnson","date":"","url":""},{"title":"2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with","source":"","date":"","url":""},{"title":"www.investor.jnj.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T","url":"https://drugnews.com.tw/assets/articles/jnj-auto-car-t-commercial-challenge/dcard-01.webp"},{"alt":"Dcard 原圖：Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T","url":"https://drugnews.com.tw/assets/articles/jnj-auto-car-t-commercial-challenge/dcard-02.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/jnj-auto-car-t-commercial-challenge/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-17）。Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T。https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-17-jnj-auto-car-t-commercial-challenge-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}